John W. Walsh Alpha-1 Home Infusion Act of 2025

This bill adds Medicare coverage for home-based treatment of Alpha-1 Antitrypsin Deficiency Disorder (a rare genetic condition causing lung and liver damage). It specifically covers "augmentation therapy" (replacement protein therapy) delivered at home by qualified suppliers to Medicare Part A and B enrollees with this diagnosis who aren't in Medicare Advantage plans. The bill establishes payment for intravenous kits and up to 2 hours of nursing services per session, set at 80% of the lesser of actual cost or a defined rate. It amends Medicare rules to include this treatment under coverage, effective January 2027.